Previous issue | Volume 98 | ESPE2024

62nd Annual ESPE (ESPE 2024)

Liverpool, UK
16 Nov 2024 - 18 Nov 2024

Card image cap
The 62nd ESPE Annual Meeting will now be taking place in Liverpool, UK.

Symposia

New Adjuvant Therapy in Pediatric Diabetes (Joint ISPAD‐ESPE Symposium)

hrp0098s4.1 | New Adjuvant Therapy in Pediatric Diabetes (Joint ISPAD‐ESPE Symposium) | ESPE2024

Use of Verapamil in newly diagnosed T1D

Forlenza Gregory

In preclinical studies, thioredoxin-interacting protein overexpression induces pancreatic beta cell apoptosis and is involved in glucotoxicity-induced beta cell death. Calcium channel blockers reduce these effects and may be beneficial to beta cell preservation in type 1 diabetes. We aimed to determine the effect of verapamil on pancreatic beta cell function in children and adolescents with newly diagnosed type 1 diabetes. This double-blind, randomized clinical trial including...

hrp0098s4.3 | New Adjuvant Therapy in Pediatric Diabetes (Joint ISPAD‐ESPE Symposium) | ESPE2024

Statins and cardiovascular risk in type 1 diabetes

Marcovecchio Loredana

Cardiovascular disease (CVD) remains the main cause of morbidity and mortality in individuals with type 1 diabetes (T1D). Although the clinical manifestations of CVD are almost exclusively observed in adult life, their incidence represents the result of a long subclinical disease process, which is largely driven by potentially modifiable risk factors, including not only hyperglycaemia but also dyslipidaemia, hypertension, obesity, insulin resistance, lifestyle habits. In indiv...